Outcomes and Effect of Radiotherapy in Patients With Stage I or II Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 5, 2008, Pages 1465-1471

  Ballonoff, Ari ^a   Rusthoven, Kyle E ^a   Schwer, Amanda ^a   McCammon, Robert ^a   Kavanagh, Brian ^a   Bassetti, Michael ^a   Newman, Francis ^a   Rabinovitch, Rachel ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Diffuse large B cell lymphoma; Early stage; Outcomes; Radiotherapy; SEER

Indexed keywords

COMPUTER OPERATING SYSTEMS; DECISION MAKING; PATIENT MONITORING; RADIOTHERAPY; SHELTERS (FROM ATTACK);

DATA SETS; DIFFUSE LARGE B-CELL LYMPHOMA; EARLY STAGE; HAZARD RATIOS; MULTIVARIATE ANALYSES; OUTCOMES; OVERALL SURVIVALS; SEER;

MULTIVARIANT ANALYSIS;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 56349143346     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.068     Document Type: Article

References (21)

1. Kaminski M.S., Coleman C.N., Colby T.B., et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104 (1986) 747-756
2. Tondini C., Zanini M., Lombardi F., et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol 11 (1993) 720-725
3. Prestidge B.R., Horning S.J., and Hoppe R.T. Combined modality therapy for stage I-II large cell lymphoma. Int J Radiat Oncol Biol Phys 15 (1988) 633-639
4. Yahalom J., Varsos G., Fuks Z., et al. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma: Results of a prospective randomized study. Cancer 71 (1993) 2342-2350
5. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
6. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 3121-3127
7. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
8. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
9. Horning S.J., Weller E., Kim K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038
10. Reyes F., Lepage E., Ganem G., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (2005) 1197-1205
11. Bonnet C., Fillet G., Mounier N., et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25 (2007) 787-792
12. Miller T.P., Leblanc M., Spier C.M., et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. [Abstract]. Blood 98 Suppl. (2001) S742-S743
13. Surveillance, Epidemiology and End-Results program Web site: Information about. Available from: http://seer.cancer.gov/about/. Accessed May 2007.
14. Fritz A, Ries C. SEER extent of disease-1988 codes and coding instructions. 3rd ed., Available from: http://seer.cancer.gov/manuals/EOD10Dig.3rd.pdf. Accessed May 2007.
15. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging handbook. sixth edition (2002), Springer, New York (NY)
16. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-458
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
18. Cox D.R. Regression models and life-tables. JR Stat Soc [B] 34 (1972) 187-202
19. Shipp M.A., Harrington D.P., Anderson J.R., et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
20. Vokes E.E., Ultmann J.E., Golomb H.M., et al. Long term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 3 (1985) 1309-1317
21. Shenkier T., Voss N., Fairey R., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20 (2002) 197-204